Real-world efficacy and safety of Arbidol in the treatment of influenza-like illness

Real World Evidence of Clinical Efficiency and Safety of Arbidol in Treatment of Influenza-like illness

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040924

Enrollment

Unknown

Registered

2020-12-15

Start date

2020-12-14

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza-like illness(ILI)

Interventions

experimental group:Arbidol

control group:Oseltamivir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who are fully informed and agree to participate in this study; 2. Axillary temperature >= 37.3 degrees C; 3. Presenting with ILI symptoms during a period of increased influenza activity, at least one each of the following respiratory and general symptoms; (1)Respiratory symptoms (sore throat, nasal congestionrunny nose ,cough, and expectoration, etc); (2)General symptoms (headache, muscle or joint pain, feverishness or chills, and fatigue, etc ).

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or breastfeeding. 2. A history of hypersensitivity to arbidol or oseltamivir.

Design outcomes

Primary

Measure	Time frame
Time to resolution of fever;Frequencies of adverse events (AEs) and treatment-related AEs;	—

Secondary

Measure	Time frame
Time to alleviation of ILI symptoms;Frequencies of complications related to ILI;Hospitalization rate of outpatients related to ILI;New infections within the household;	—

Countries

China

Contacts

Public ContactGang Wang

Qilu Hospital of Shandong University

wangg1975@hotmail.com+86 18560082130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026